HF
BBIO icon

HRT Financial’s BridgeBio Pharma BBIO Stock Holding History

HRT Financial’s Portfolio BBIO Stock Details BBIO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$81.1M Buy
1,089,376
+1,017,511
+1,416% +$71.3M 0.15% 110
2026
Q1 		$5.34M Buy
71,865
+30,766
+75% +$2.23M 0.01% 951
2025
Q4 		$3.14M Sell
41,099
-20,202
-33% -$1.33M 0.01% 1016
2025
Q3 		$3.18M Buy
+61,301
New +$2.99M 0.01% 899
2024
Q2 		– Sell
-16,524
Closed -$510K – 2218
2024
Q1 		$510K Buy
+16,524
New +$562K ﹤0.01% 1248
2023
Q4 		– Sell
-37,211
Closed -$981K – 2314
2023
Q3 		$981K Buy
+37,211
New +$1.06M 0.01% 988
2023
Q2 		– Sell
-162,406
Closed -$2.69M – 2467
2023
Q1 		$2.69M Buy
162,406
+56,770
+54% +$662K 0.03% 466
2022
Q4 		$804K Buy
105,636
+10,488
+11% +$100K 0.01% 1090
2022
Q3 		$945K Buy
95,148
+77,921
+452% +$810K 0.01% 973
2022
Q2 		$156K Buy
+17,227
New +$144K ﹤0.01% 2324
2022
Q1 		– Sell
-53,138
Closed -$886K – 3098
2021
Q4 		$886K Sell
53,138
-191,518
-78% -$8.1M 0.01% 1238
2021
Q3 		$11.5M Buy
+244,656
New +$13.1M 0.07% 131

Other funds holding BBIO

JT
Jupiter Topco New York $245B AUM
KKRC
Kohlberg Kravis Roberts & Co New York $5.71B AUM 72.37% 1-Year Est. Return
FCM
Farallon Capital Management San Francisco, California $21.7B AUM 79.24% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Viking Global Investors
Viking Global Investors Stamford, Connecticut $35.1B AUM 21.36% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Wellington Management Group
Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return
Two Sigma Investments
Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return
ACM
Aisling Capital Management New York $472M AUM 106.83% 1-Year Est. Return

HRT Financial's BBIO Position: Q2 2026 in Review

HRT Financial increased its BridgeBio Pharma (BBIO) stake by 1,416% in Q2 2026, buying an estimated $71.3M and bringing the position to 1,089,376 shares worth $81.1M. The position accounts for 0.15% of the portfolio, ranked #110.

HRT Financial first reported a position in BBIO in Q3 2021 and has held it in 12 quarters since. 475 funds tracked by Wall St. Rank hold BBIO as of Q2 2026.

  • HRT Financial held 1,089,376 shares of BridgeBio Pharma worth $81.1M as of Q2 2026.
  • HRT Financial bought 1,017,511 BridgeBio Pharma shares in Q2 2026, an estimated $71.3M.
  • BridgeBio Pharma made up 0.15% of HRT Financial's portfolio in Q2 2026, its #110 holding.
  • HRT Financial first reported a position in BridgeBio Pharma in Q3 2021 and has held it in 12 quarters since.
  • 475 funds tracked by Wall St. Rank held BridgeBio Pharma as of Q2 2026.

Based on HRT Financial's 13F filing for Q2 2026, filed 14 Aug 2026.